Who is sponsoring NCT03939234?

NCT03939234 is sponsored by Lars Møller Pedersen.

What drugs are being tested in NCT03939234?

Interventions in NCT03939234: PD-L1, PD-L2 peptides with Montanide ISA51.

What condition does NCT03939234 study?

NCT03939234 studies Chronic Lymphocytic Leukemia.

Is NCT03939234 still recruiting?

NCT03939234 is currently completed. Last updated 21 February 2022.

Last reviewed 2022-02-21 · How we verify

NCT03939234

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Completed Phase 2 Last updated 21 February 2022

What this trial tests

Phase 2 trial testing PD-L1, PD-L2 peptides with Montanide ISA51 in Chronic Lymphocytic Leukemia in 19 participants. Completed in 15 March 2021.

Timeline

26 April 2019

Primary endpoint
15 March 2021

15 March 2021

Quick facts

Lead sponsor	Lars Møller Pedersen
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	26 April 2019
Primary completion	15 March 2021
Estimated completion	15 March 2021
Sites	1 location across Denmark

Drugs / interventions tested

PD-L1, PD-L2 peptides with Montanide ISA51

Conditions studied

Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →

Sponsor

Lars Møller Pedersen — full company profile →

Who can join

18 and older, any sex, with Chronic Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is investigating the efficacy of PD-L1 and PD-L2 peptides in untreated CLL patients with unmutated IGHV gene status.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.
Stephens AJ, Burgess-Brown NA, Jiang S. · · 2021 · cited 112× · PMID 34276688 · DOI 10.3389/fimmu.2021.696791
Development of Peptide-Based Vaccines for Cancer.
Abd-Aziz N, Poh CL. · · 2022 · cited 100× · PMID 35342400 · DOI 10.1155/2022/9749363
Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
Solinas C, Aiello M, Rozali E, Lambertini M, et al · · 2020 · cited 61× · PMID 32622310 · DOI 10.1016/j.tranon.2020.100811
Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.
Jørgensen NG, Klausen U, Grauslund JH, Helleberg C, et al · · 2020 · cited 25× · PMID 33240282 · DOI 10.3389/fimmu.2020.595035
SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade.
Kao WH, Liao LZ, Chen YA, Lo UG, et al · · 2024 · cited 15× · PMID 39284838 · DOI 10.1038/s41419-024-07044-3
Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.
Zhang X, Wu Y, Lin J, Lu S, et al · · 2024 · cited 13× · PMID 39309492 · DOI 10.1016/j.apsb.2024.05.013
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.
Klausen U, Grauslund JH, Jørgensen NGD, Ahmad SM, et al · · 2022 · cited 5× · PMID 36483037 · DOI 10.3389/fonc.2022.1023015
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.
Englisch A, Hayn C, Jung S, Heitmann JS, et al · · 2024 · cited 4× · PMID 39252947 · DOI 10.3389/fonc.2024.1441625

Verify or expand the search:

Other recruiting trials for Chronic Lymphocytic Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT07288515 — Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus · recruiting
NCT07014917 — Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL · Phase 2 · recruiting

Other Lars Møller Pedersen trials

Trials by the same sponsor.

NCT06161896 — Characterization and Clinical Impact of the Gut Microbiota in Lymphoma · recruiting
NCT04492553 — Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality · Phase 2 · completed
NCT04630275 — Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality-Obs · completed
NCT03381768 — Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03939234 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lars Møller Pedersen
Last refreshed: 21 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03939234.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing